Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug

被引:9
作者
Kondo, T [1 ]
Tanaka, O [1 ]
Otani, K [1 ]
Mihara, K [1 ]
Tokinaga, N [1 ]
Kaneko, S [1 ]
Chiba, K [1 ]
Ishizaki, T [1 ]
机构
[1] INT MED CTR JAPAN,RES INST,DEPT CLIN PHARMACOL,TOKYO 162,JAPAN
关键词
zotepine; metabolism; smoking; CYP2C19; diazepam;
D O I
10.1007/BF02806008
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Effects of smoking and cytochrome P450 2C19 (CYP2C19) status on the single dose kinetics of zotepine and pharmacokinetic interaction between zotepine and diazepam were investigated. In 14 healthy volunteers, the pharmacokinetics of zotepine after a single oral 25 mg dose were compared between eight smokers and six non-smokers, or between seven extensive metabolizers (EMs) and seven poor metabolizers (PMs) of S-mephenytoin. There was no significant difference in any pharmacokinetic parameters between smokers and non-smokers, or between the EM and PM groups. In 17 patients treated with zotepine 80-340 mg/day, intra-individual changes in plasma concentrations of zotepine caused by coadministration of diazepam 10 mg/day for 2 weeks were examined. Plasma concentrations of zotepine were significantly increased after coadministration of diazepam (P < 0.05). Consequently, it is suggested that neither smoking nor CYP2C19 status affects the metabolism of zotepine. The elevation in plasma concentrations of zotepine after coadministration of diazepam may be a result of competitive inhibition of zotepine metabolism by diazepam via other isoenzyme than CYP2C19, e.g., CYP3A4.
引用
收藏
页码:311 / 314
页数:4
相关论文
共 21 条
  • [1] DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS
    ANDERSSON, T
    MINERS, JO
    VERONESE, ME
    BIRKETT, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (02) : 131 - 137
  • [2] ZOTEPINE IN THE TREATMENT OF SCHIZOPHRENIC-PATIENTS WITH PREVAILINGLY NEGATIVE SYMPTOMS - A DOUBLE-BLIND TRIAL VS HALOPERIDOL
    BARNAS, C
    STUPPACK, CH
    MILLER, C
    HARING, C
    SPERNERUNTERWEGER, B
    FLEISCHHACKER, WW
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1992, 7 (01) : 23 - 27
  • [3] IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE
    BERTILSSON, L
    HENTHORN, TK
    SANZ, E
    TYBRING, G
    SAWE, J
    VILLEN, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) : 348 - 355
  • [4] THE INFLUENCE OF ENVIRONMENTAL AND GENETIC-FACTORS ON CYP2D6, CYP1A2 AND UDP-GLUCURONOSYLTRANSFERASES IN MAN USING SPARTEINE, CAFFEINE, AND PARACETAMOL AS PROBES
    BOCK, KW
    SCHRENK, D
    FORSTER, A
    GRIESE, EU
    MORIKE, K
    BROCKMEIER, D
    EICHELBAUM, M
    [J]. PHARMACOGENETICS, 1994, 4 (04): : 209 - 218
  • [5] DISPOSITION OF PERPHENAZINE IS RELATED TO POLYMORPHIC DEBRISOQUIN HYDROXYLATION IN HUMAN-BEINGS
    DAHLPUUSTINEN, ML
    LIDEN, A
    ALM, C
    NORDIN, C
    BERTILSSON, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (01) : 78 - 81
  • [6] EFFECTS OF SMOKING ON FLUPHENAZINE CLEARANCE IN PSYCHIATRIC-INPATIENTS
    ERESHEFSKY, L
    JANN, MW
    SAKLAD, SR
    DAVIS, CM
    RICHARDS, AL
    BURCH, NR
    [J]. BIOLOGICAL PSYCHIATRY, 1985, 20 (03) : 329 - 352
  • [7] FLEISCHHACKER WW, 1989, PSYCHOPHARMACOL BULL, V25, P97
  • [8] METOPROLOL AND MEPHENYTOIN OXIDATION POLYMORPHISMS IN FAR EASTERN ORIENTAL SUBJECTS - JAPANESE VERSUS MAINLAND CHINESE
    HORAI, Y
    NAKANO, M
    ISHIZAKI, T
    ISHIKAWA, K
    ZHOU, HH
    ZHOU, BJ
    LIAO, CL
    ZHANG, LM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (02) : 198 - 207
  • [9] A STUDY OF THE THERAPEUTIC SPECTRUM OF A FIXED-DOSE OF ZOTEPINE AND ITS RELATIONSHIP WITH SERUM CONCENTRATIONS OF THE DRUG
    KONDO, T
    OTANI, K
    ISHIDA, M
    MIHARA, K
    TANAKA, O
    KANEKO, S
    FUKUSHIMA, Y
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1993, 8 (02) : 133 - 139
  • [10] ADVERSE-EFFECTS OF ZOTEPINE AND THEIR RELATIONSHIP TO SERUM CONCENTRATIONS OF THE DRUG AND PROLACTIN
    KONDO, T
    OTANI, K
    ISHIDA, M
    TANAKA, O
    KANEKO, S
    FUKUSHIMA, Y
    [J]. THERAPEUTIC DRUG MONITORING, 1994, 16 (02) : 120 - 124